액체 생검은 체액을 순환하는 종양 유래 물질을 분석하여 암의 진단, 치료 및 모니터링을 위한 귀중한 정보를 제공하는 최소 침습적 진단 도구로 등장했습니다. 조직 생검과 영상 진단 기술이 여전히 고형암 진단의 표준이지만, 액체 생검은 기존 방법의 한계와 위험성을 극복할 수 있는 대체 또는 보완적인 접근법입니다.
본 보고서는 세계의 액체 생검(Liquid Biopsy) 시장에 대해 조사했으며, 시장 개요와 함께 분석 대상별/용도별/암종별/지역별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 액체생검 기술
제3장 순환 종양 DNA(ctDNA) 액체생검
제4장 순환종양세포(CTC) 액체생검
제5장 세포외소포 및 기타 액체생검
제6장 복수 검체 액체생검 검사
제7장 연구 목적의 액체생검 검사
제8장 액체생검 업계 분석
- 서론
- 경쟁 단계
- 경쟁 요인
- 중요 시장 동향
- 맞춤형 의료
- 세계 평균수명 연장
- 새로운 액체생검 제품
- 유전자 검사의 접근성 향상
- 규제 장벽
- 제3자 지불자의 보상 범위
- 증명된 임상적 유용성
- 특정 암의 발생률
- 경쟁사는 액체생검 시장에서 철퇴
제9장 액체생검 시장
제10장 분석 대상물별 시장
- 순환종양 DNA
- 순환종양 세포
- 세포외소포 및 기타
제11장 용도별 시장
- 치료 가이던스 및 모니터링
- 진단 및 스크리닝
- 질병의 예후
제12장 암 유형별 시장
제13장 기업 개요
- 시장 기업
- Adaptive Biotechnologies
- Agena Bioscience, Inc
- ANGLE, plc
- Aspira Women's Health
- Biocartis Group NV
- Biocept, Inc.
- Biodesix
- CellMax Life
- Circulogene
- DiaCarta, Inc
- Epic Sciences
- Epigenomics AG
- Exact Sciences
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc.
- Freenome, Inc
- GILUPI GmbH
- GRAIL
- Guardant Health, Inc
- Hologic
- LungLife AI
- Menarini-Silicon Biosystems, Spa
- Myriad Genetics, Inc
- Natera, Inc
- NeoGenomics Laboratories, Inc
- Oncocyte Corporation
- OncoDNA S.A.
- Personal Genome Diagnostics
- QIAGEN N.V.
- Resolution Biosciences
- Roche Diagnostics
- Sysmex-Inostics, Inc
- Tempus
- VolitionRx
LSH
Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods.
Key applications of liquid biopsy testing in clinical oncology include:
1. Early Detection and Diagnosis/Screening:
- Identifying cancer at an early stage.
2. Alternative Testing Method:
- When tissue biopsy is challenging or impossible.
- When the primary site of metastatic disease is unknown.
3. Therapy Personalization and Monitoring:
- Molecular characterization to select optimal therapy.
- Monitoring treatment efficacy and adjusting therapy in case of resistance.
4. Disease Monitoring:
- Observing disease progression, tumor evolution, residual disease.
- Early detection of recurrence.
5. Prognosis of Disease:
- Assessing the likely course and outcome of the disease.
The liquid biopsy market is experiencing significant changes, and “ The Worldwide Market for Liquid Biopsy, 6th Edition ” from Kalorama Information provides an in-depth assessment of the market opportunity from 2023 to 2028. The brand new market research report covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types.
Key Market Segments:
- By Region:
- North America
- Europe
- Asia
- Rest of World
- By Type of Liquid Biopsy:
- CTC-based Liquid Biopsy
- ctDNA-based Liquid Biopsy
- EV and Exosome-based Liquid Biopsy
- Multi-Analyte-based Liquid Biopsy
- Other Analytes Liquid Biopsy
- By Type of Cancer:
- Breast
- Lung
- Colorectal
- Ovarian
- Prostate
- Pan-Cancer
- Other Cancers
- R&D and Selected Tests:
- Selected ctDNA-based Liquid Biopsy Tests in Development
- Selected CTC-based Liquid Biopsy Tests in 2023
- Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023
The growing acceptance of liquid biopsy, even during the 6th pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy's potential in combination with other technologies further contributes to its expanding applications and market growth.
The report also profiles key companies in the liquid biopsy market. These include:
Top of Form
Bottom of Form
- Adaptive Biotechnologies
- Agena Bioscience, Inc.
- Angle, PLC
- Aspira Women's Health
- Biocartis Group Nv
- Biocept, Inc. (closed)
- Biodesix
- Cellmax Life
- Circulogene
- Diacarta, Inc.
- Epic Sciences
- Epigenomics AG (closed)
- Exact Sciences
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc. (Roche)
- Freenome, Inc.
- Gilupi Gmbh
- Grail (Illumina)
- Guardant Health, Inc.
|
- Hologic
- Lunglife AI (Formerly Cynvenio Biosystems)
- Menarini-Silicon Biosystems, SPA
- Myriad Genetics, Inc.
- Natera, Inc.
- Neogenomics Laboratories, Inc.
- Oncocyte Corporation
- Oncodna S.A.
- Personal Genome Diagnostics
- Qiagen N.V.
- Cell-Free DNA Technologies
- Ctc Technologies
- Exosome And Mirna Technologies
- Resolution Biosciences (Agilent)
- Roche Diagnostics
- Sysmex-Inostics, Inc.
- Tempus
- Volitionrx
|
Table of Contents
Chapter One: Executive Summary
- Introduction
- Liquid Biopsy Technologies
- Industry Structure
- Liquid Biopsy Market Revenues and Forecast
- Figure 1-1: Market for Liquid Biopsy, 2023-2028 ($M)
- Figure 1-2: Global Liquid Biopsy Market Share, by Geographic Region, 2023 (%)
- Table 1-1: Global Liquid Biopsy Market by Geographic Region, 2023-2028 ($M)
Chapter Two: Liquid Biopsy Technologies
- Introduction
- Table 2-1: Comparison of Tissue and Liquid Biopsy
- Current Major Liquid Biopsy Technologies
- Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy
- Introduction
- Advantages and Limitations of ctDNA in Liquid Biopsy
- Current ctDNA-based Liquid Biopsy Tests
- Table 3-1: Selected ctDNA-based Liquid Biopsy Tests, 2023
- Biocartis
- Biodesix
- CellMax Life
- Circulogene
- Diacarta
- Foundation Medicine (Roche)
- Guardant Health
- Inivata (Neogenomics)
- LungLife AI
- Myriad Genetics
- NeoGenomics
- OncoDNA
- Personal Genomic Diagnostics (LabCorp)
- QIAGEN
- Resolution Biosciences (Exact Sciences)
- Roche Diagnostics
- Sysmex-Inostics
- Tempus
- ctDNA-based Liquid Biopsy Tests in Development
- Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development, 2023
- Freenome
- GRAIL
Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy
- Introduction
- Challenges in the Development of CTC-based Liquid Biopsy Tests
- CTC-based Liquid Biopsy Tests
- Table 4-1: Selected CTC-based Liquid Biopsy Tests, 2023
- Adaptive Biotechnologies
- ANGLE
- CellMax Life
- Epic Sciences
- GILUPI
- LungLife AI
- Menarini-Silicon Biosystems
- QIAGEN
- Selected CTC-based Liquid Biopsy Tests in Development
- Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2023
- Epic Sciences
- Liquid Biotech USA
Chapter Five: Extracellular Vesicles and Other Liquid Biopsy
- Introduction
- Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
- Table 5-1: Selected Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2023
- Aspira Women's Health (formerly Vermillion)
- Biodesix
- Exosome Diagnostics
- Hologic
- MDxHealth
- Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
- Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2023
- Circulogene
- OncoCyte
- Resolution Biosciences (Exact Sciences)
- VolitionRx
Chapter Six: Multi-Analyte Liquid Biopsy Tests
- Introduction
- Liquid Biopsy Tests Based on Multiple Analytes
- Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2023
- Biodesix
- Foundation Medicine (Roche)
- LungLife AI
- NeoGenomics
- OncoDNA
- Multiple Analyte-based Liquid Biopsy Tests in Development
- Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2023
- Exact Sciences
- Freenome
- GRAIL
- LungLife AI
Chapter Seven: Liquid Biopsy Tests for Research Use Only
- Introduction
- Liquid Biopsy Tests for Research Use Only
- Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2023
- Agena Bioscience
- DiaCarta
- Exosome Diagnostics
- Guardant Health
- Natera
- QIAGEN
Chapter Eight: Liquid Biopsy Industry Analysis
- Introduction
- Tiers of Competition
- Table 8-1: Selected Participants in the Liquid Biopsy Market, 2023
- Competitive Factors
- Significant Market Trends
- Table 8-2: Significant Trends in the Liquid Biopsy Market, 2023
- Personalized Medicine
- Increasing Global Life Expectancy
- New Liquid Biopsy Products
- Increasing Accessibility of Genetic Testing
- Regulatory Hurdles
- Third-Party Payor Coverage
- Demonstrated Clinical Utility
- Incidence Rates of Specific Cancers
- Competitors No Longer in the Liquid Biopsy Market
- Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market
Chapter Nine: Liquid Biopsy Market
- Market Overview
- Table 9-1: Global Liquid Biopsy Diagnostics Market Estimate, by Region, 2023-2028 ($M)
- Figure 1-2: Global Liquid Biopsy Market, by Geographic Region, 2023 ($M)
- Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimated Share, by Region, 2023 (%)
- Market Forecast
- Figure 9-3: Global Liquid Biopsy Market Forecast, by Region (North America, Europe, Asia Pacific, Rest of World), 2023-2028 ($M)
Chapter Ten: Market by Analyte
- Circulating Tumor DNA
- Market Overview
- Applications
- Technologies
- Specimens
- Revenue Forecast
- Table 10-1: Global Liquid Biopsy Market for ctDNA, 2023-2028 ($M)
- Circulating Tumor Cells
- Market Overview
- Applications
- Technologies
- Specimens
- Revenue Forecast
- Table 10-2: Global Liquid Biopsy Market for CTCs, 2023-2028 ($M)
- Extracellular Vesicles and Other Analytes
- Market Overview
- Applications
- Technologies
- Specimens
- Revenue Forecast
- Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles, 2023-2028 ($M)
- Multiple Analytes
- Market Overview
- Revenue Forecast
- Table 10-4: Global Liquid Biopsy Market for Multiple Analytes, 2023-2028 ($M)
Chapter Eleven: Market by Application
- Therapy Guidance and Monitoring
- Market Overview
- Revenue Forecast
- Table 11-1: Liquid Therapy for Therapy Guidance, 2023-2028 ($M)
- Diagnosis/Screening
- Market Overview
- Revenue Forecast
- Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening, 2023-2028 ($M)
- Disease Prognosis
- Market Overview
- Revenue Forecast
- Table 11-3: Global Liquid Biopsy Market for Disease Prognosis, 2023-2028 ($M)
Chapter Twelve: Market by Cancer Type
- Breast Cancer
- Market Overview
- Revenue Forecast
- Table 12-1: Global Liquid Biopsy Market for Breast Cancer, 2023-2028 ($M)
- Colorectal Cancer
- Market Overview
- Revenue Forecast
- Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer, 2023-2028 ($M)
- Lung Cancer
- Market Overview
- Revenue Forecast
- Table 12-3: Global Liquid Biopsy Market for Lung Cancer, 2023-2028 ($M)
- Ovarian Cancer
- Market Overview
- Revenue Forecast
- Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer, 2023-2028 ($M)
- Prostate Cancer
- Market Overview
- Revenue Forecast
- Table 12-5: Global Liquid Biopsy Market for Prostate Cancer, 2023-2028 ($M)
- Other Cancers
- Market Overview
- Revenue Forecast
- Table 12-6: Global Liquid Biopsy Market for Other Cancers, 2023-2028 ($M)
- Pan-Cancer Tests
- Market Overview
- Revenue Forecast
- Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing, 2023-2028 ($M)
Chapter Thirteen: Company Profiles
- Companies in the Market
- Table 13-1 Companies in the Liquid Biopsy Market
- Adaptive Biotechnologies
- Agena Bioscience, Inc.
- ANGLE, plc
- Aspira Women's Health
- Biocartis Group NV
- Biocept, Inc. (closed)
- Biodesix
- CellMax Life
- Circulogene
- DiaCarta, Inc.
- Epic Sciences
- Epigenomics AG (closed)
- Exact Sciences
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc. (Roche)
- Freenome, Inc.
- GILUPI GmbH
- GRAIL (Illumina)
- Guardant Health, Inc.
- Hologic
- LungLife AI (formerly Cynvenio Biosystems)
- Company Overview
- Company Overview
- Menarini-Silicon Biosystems, Spa
- Myriad Genetics, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Oncocyte Corporation
- OncoDNA S.A.
- Personal Genome Diagnostics
- QIAGEN N.V.
- Cell-free DNA Technologies
- CTC Technologies
- Exosome and miRNA Technologies
- Resolution Biosciences (Agilent)
- Roche Diagnostics
- Sysmex-Inostics, Inc.
- Tempus
- VolitionRx
